Control and Prevention of Malaria Project (CAP-Malaria)


This project aims to prevent malaria and contain the spread of multi-drug resistant Plasmodium falciparum (P. falciparum) malaria in the Greater Mekong Subregion. P. falciparum is the most common and the most deadly parasite that causes malaria in humans. The best available treatment, particularly for P. falciparum malaria, is artemisinin-based combination therapy (ACT).

A second challenge is the quality of treatment: self-medication and poor treatment, particularly in the unregulated private sector, make it increasingly difficult to ensure proper drug use. Counterfeit and substandard antimalarial medications–which can cause death, undermine confidence in malaria treatment, and increase drug resistance–are also highly prevalent.

Key Activities

  • Develop and scale up cost-effective vector control interventions to prevent the transmission of malaria
  • Improve the quality and effectiveness of diagnosis and treatment of malaria at the community and health facility levels
  • Reduce management bottlenecks of national malaria control programs and local institutions to implement and monitor malaria control activities
  • Support the establishment and maintenance of strategic information for malaria control

The CAP-Malaria Project is funded by United States Agency for International Development (USAID) RDMA under Cooperative Agreement Number AID-486-A-12-00001. The project team includes prime recipient University Research Co., LLC (URC) and sub-recipient organizations, including Save the Children.

The picture shows one forest goer family who receiving the LLIN through the identified touch point in Siem Pang district of Stung Treng province.
In Cambodia, a family receives their LLIN through the identified touch point in Siem Pang district of Stung Treng province
2011 to 2016
US Agency for International Development (USAID)
Save the Children Myanmar
Kenan Institute Asia
Regions/ Countries 
Geographic Scope 
Greater Mekong Sub-region